We have discussed about CLARIS LIFE SCIENCES earlier and mentioned that the history of its promoters ( related with Core Healthcare issue )as one of the big negative factor.During the last one year some positives happened for Claris. First one is the approval of the Medicines and Healthcare Product Regulatory Agency (MHRA-UK) which enables the company to relaunch its Bag Products in European Union. EU is the second largest market for injectable products.Its Ahmadabad facility is also expecting positive outcome from the recent inspection of USFDA.Both these approvals will help the company to improve its sales.Another factor is the possibility of a re-rating in Parenteral manufacturers after the acquisition of Ahlcon Parenterals by the German healthcare products major B Braun at a valuation of Rs.331 Cr which is at 23x its trailing EBITDA and over 57x its trailing net profit.Third point is the recent entry of some institutional investors and individual investors with repute ,in this company.Morgan Stanley recently bought 5 lac shares of Claris @ Rs.155.50/- and Shivanand Shankar Manekar bought 7 lac shares@Rs.140/-. If there is no negative surprise from recent USFDA authoritie's visit and good standard of corporate governance by the company may help it to re-rate in medium to long term .CMP is Rs.158/-
For old posting on this company,Click HERE
